Dacomitinib (PF-00299804), an Irreversible Pan-Her Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-11-0730
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)